Ophthalmic Surgery, Lasers and Imaging Retina

Practical Retina Free

The Role of NSAIDs in the Management of Macular Edema

Angela P. Bessette, MD; Seenu M. Hariprasad; Rishi P. Singh, MD

Seenu M. Hariprasad, Practical Retina Co-Editor

Seenu M. Hariprasad
Practical Retina Co-Editor

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used for years by our anterior segment colleagues in the postoperative period for patients undergoing cataract surgery. Recently, there has been an increasing interest in the posterior segment world given emerging evidence that NSAIDs may have a beneficial effect on posterior segment inflammation and macular edema. Just within the past year, nepafenac gained a label in the U.K. for the prevention of macular edema following cataract surgery in diabetic patients — a well-known high-risk population.

Angela P. Bessette, MD, and Rishi P. Singh, MD, will provide an overview of the literature and summarize the current thinking regarding use of NSAIDs for the management of posterior segment disease. They will focus on prophylaxis and the treatment of pseudophakic macular edema; the treatment of diabetic macular edema; and, lastly, the treatment of uveitic macular edema. Furthermore, they will review current recommendations of the American Society of Cataract and Refractive Surgery regarding use of NSAIDs for the prevention of pseudophakic macular edema.

I am certain that our readers will find Drs. Bessette and Singh's insights to be thought-provoking and will value their review of this complex and long-debated topic.

Angela P. Bessette

Angela P. Bessette

Rishi P. Singh

Rishi P. Singh

Nonsteroidal anti-inflammatory drugs (NSAIDs) are potent inhibitors of the enzyme, cyclooxygenase (COX), a key catalyst in the inflammatory pathway. As such, they are widely utilized by physicians for their analgesic, antipyretic, and anti-inflammatory properties. Activation of the COX pathway leads to the production of prostaglandins. Within the eye, prostaglandins promote miosis, vasodilation, disruption of the blood-ocular barrier, and leukocyte migration.1 Ophthalmologists commonly use topical NSAIDs to decrease postoperative inflammation, limit intraoperative miosis, and prevent and treat macular edema associated with cataract surgery.1 Several topical preparations of NSAIDs are currently available for ophthalmic use, including flurbiprofen, diclofenac, ketorolac, bromfenac, and nepafenac. Newer NSAIDs, including bromfenac and nepafenac, were formulated to have greater corneal penetration and, in preclinical studies, were shown to have higher concentrations in ocular tissues, including the retina.1–3 Given the potential for better drug delivery to the posterior segment with newer NSAIDs and a growing body of evidence that implicates inflammation in the pathogenesis of macular edema associated with diabetes and retinal vein occlusions (RVOs),4,5 there is renewed interest in the role of topical NSAIDs to treat retinal disease.

Prophylaxis of Pseudophakic Macular Edema

Cystoid macular edema (CME) is a common cause of vision loss following cataract surgery, especially in patients with uveitis or diabetes. NSAIDs are commonly prescribed by cataract surgeons in the perioperative period, and many studies have evaluated their effect on surgical outcomes. Pretreatment with NSAIDs for 1 day to 3 days prior to cataract surgery has been shown to give better visual acuity outcomes in the immediate postoperative period compared to placebo; however, the effects are lost by 90 days.6 The role of NSAIDs in preventing macular edema related to cataract surgery is controversial. In a multicenter, placebo-controlled trial in patients with nonproliferative diabetic retinopathy (NPDR), nepafenac 0.1% decreased the incidence of postoperative macular edema within 90 days of cataract surgery and showed early visual acuity benefits.7 These results have since been supported by two multicenter, vehicle-controlled trials of nepafenac 0.3% in patients with NPDR in which the pooled analysis of the efficacy endpoints showed a significant number of nepafenac-treated patients achieving a three-line gain in visual acuity versus vehicle-treated patients.8 These studies led to the approval of nepafenac by the European Medicines Agency for the prevention of macular edema in patients with diabetes undergoing cataract surgery.9 Nepafenac has also recently been labeled in the United Kingdom for the prevention of macular edema following cataract surgery in diabetic patients.10

The evidence for NSAID use in routine cataract surgery in nondiabetic patients is less compelling. A prospective, randomized, controlled trial comparing ketorolac, nepafenac, and placebo found no difference between the groups in the incidence of postoperative macular edema.11 In a recent report of the American Academy of Ophthalmology (AAO), the authors rigorously evaluated the current literature on the effectiveness of topical NSAIDs in preventing vision loss from CME after cataract surgery. They concluded that although NSAIDs are effective in reducing the incidence of optical coherence tomography (OCT)-based or angiographic CME and hastening visual recovery in the short term when compared to placebo or topical steroids, there is a lack of level I evidence to suggest that routine prophylactic use of NSAIDs reduces long-term (> 3 months) vision loss from CME after cataract surgery.12

Treatment of Pseudophakic Macular Edema

NSAIDs are commonly used by retina specialists early in the treatment algorithm for pseudophakic CME (PCME) in combination with topical corticosteroids. Pseudophakic CME can be classified as either acute (occurring < 4 months from surgery) or chronic (occurring > 6 months after surgery). Acute PCME has a peak incidence at 6 weeks postoperatively and often resolves without treatment.13 Heier et al. compared ketorolac monotherapy, prednisolone monotherapy, and ketorolac/prednisolone combination therapy for the treatment of acute PCME and found that combination therapy offered advantages over monotherapy with either agent.14 Another study compared diclofenac versus ketorolac monotherapy for acute PCME and found both were equally beneficial.15 Although these results are encouraging, the study groups were small and the latter study did not include a control group. The authors of a recent Cochrane review concluded that the evidence was insufficient to inform practice, but that there may be a therapeutic benefit especially if combined with topical steroids.16

That same Cochrane review uncovered four articles addressing the use of NSAIDs in the treatment of chronic PCME. The first two studies published may be less relevant at this time given they included only aphakic patients' statuses post-intracapsular cataract extraction. Each found no benefit to treatment with NSAIDs, the first to oral indomethacin and the second to topical fenoprofen.17,18 Two randomized, controlled studies by Flach et al. included patients who had undergone intracapsular and extracapsular cataract extraction. The first study, published in 1987, included 26 patients and found a statistically significant improvement in visual acuity with treatment with topical ketorolac for 2 months to 3 months compared with placebo.19 Four years later, these results were confirmed in a larger, multicenter study of 120 patients, which again found an improvement in visual acuity in patients treated with topical ketorolac for 3 months to 4 months compared to placebo.20 Although there have been several smaller, nonrandomized trials showing the benefit of treatment of chronic PCME with topical NSAIDs,21,22 the latter two studies remain the strongest evidence supporting their use for this indication.

Treatment of Diabetic Macular Edema

Given the fact that patients with diabetic retinopathy have been found to have elevated inflammatory markers and topical nepafenac has been shown to penetrate the retina in animal models, the Diabetic Retinopathy Clinical Research Network (DRCR) designed a randomized, controlled trial evaluating the use of nepafenac for non-center involving diabetic macular edema.23,24 They found no beneficial effect on OCT-based retinal thickening or visual acuity outcomes with 12 months of topical nepafenac compared to placebo.24 A Cochrane review published just prior to the DRCR trial found no other randomized, controlled trials investigating the role of NSAIDs in the treatment of diabetic macular edema.25 Thus, although nepafenac has been shown to decrease the incidence of postoperative macular edema in patients with diabetic retinopathy, there is currently insufficient evidence to suggest any role for topical NSAIDs in the treatment of diabetic macular edema.

Treatment of Uveitic Macular Edema

Although local and systemic steroids remain the standard of care for uveitic macular edema, topical NSAIDs are an attractive alternative given their anti-inflammatory capacity without the unwanted steroid-induced elevation in intraocular pressure. A placebo-controlled, randomized trial of topical 0.5% indomethacin for the treatment of acute, noninfectious uveitic macular edema showed a significant decrease in central subfield thickness on OCT at 6 months compared to placebo.26 A smaller case series reported a similar beneficial effect of topical nepafenac; however, not all results have been as promising.27 In a retrospective case series comparing topical bromfenac alone versus in combination with either intravitreal triamcinolone acetonide or bevacizumab (Avastin; Genentech, South San Francisco, CA), topical bromfenac alone had no effect on visual acuity or OCT thickness at 3 months, whereas both combination groups had significant improvement in visual acuity and OCT thickness.28 Larger randomized, controlled trials are needed to determine the role of NSAIDs in the treatment of uveitic CME.

Implications for Practice

In conclusion, the role of NSAIDs in the prevention and treatment of macular edema is evolving. Recent studies suggest that topical nepafenac may play a role in the prevention of macular edema post-cataract surgery in patients with diabetic retinopathy, which supports the popular practice of many cataract surgeons who prescribe topical NSAIDs routinely in diabetic patients undergoing cataract surgery. The use of NSAIDs for the prevention of pseudophakic macular edema in routine cataract surgery remains controversial, and more work is needed in this area. Although the panel responsible for the AAO's Ophthalmic Technology Assessment (OTA) found insufficient evidence to support their use, some have questioned their decision to use visual acuity at 3 months as their primary outcome. Some studies have suggested that NSAIDs provide more short-term benefits after cataract surgery. Thus, the American Society of Cataract and Refractive Surgeons (ASCRS) suggested that visual outcome at 1 month and patient-reported quality of life would be more appropriate end points as they would better capture any benefit NSAIDs have on hastening visual recovery after cataract surgery, and the ASCRS ultimately did not endorse the OTA report.29 Pending future work in this area, cataract surgeons need to carefully consider the current evidence and weigh the benefits of treatment in their specific patient population with the additional costs for a limited long-term benefit on visual acuity.

Although the ability of NSAIDs to prevent PCME remains controversial, their role in the treatment of PCME, particularly PCME lasting longer than 6 months in duration, has been shown and confirmed in randomized, controlled trials. There may be added benefit when used in combination with topical steroid, and this should be considered as initial treatment for PCME. Ophthalmologists have been evaluating the role of NSAIDs in the treatment of retinal disease for decades, and future well-designed trials are needed to better define their utility in the treatment and prevention of macular edema, whether alone or in combination with other topical and/or intravitreal therapeutics.

References

  1. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55(2):108–133. doi:10.1016/j.survophthal.2009.07.005 [CrossRef]
  2. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther. 2008;24(4):392–398. doi:10.1089/jop.2007.0082 [CrossRef]
  3. Ganache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000;24(4):357–370. doi:10.1023/A:1007049015148 [CrossRef]
  4. Noma H, Funatsu H, Mimura T, Eguchi S, Hori S. Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. Am J Ophthalmol. 2011;152(4):669–677. doi:10.1016/j.ajo.2011.04.006 [CrossRef]
  5. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73–79. doi:10.1016/j.ophtha.2008.09.037 [CrossRef]
  6. Donnenfeld ED, Perry HD, Wittpenn JR, Solomon R, Nattis A, Chou T. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmokinetic-response curve. J Cataract Refract Surg. 2006;32(9):1474–1482. doi:10.1016/j.jcrs.2006.04.009 [CrossRef]
  7. Singh R, Alpern L, Jaffe GJ, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259–1269. doi:10.2147/OPTH.S31902 [CrossRef]
  8. Lehmann R, et al. Clinical efficacy and safety of once-daily nepafenac 0.3% in patients with diabetic retinopathy having cataract surgery. Paper presented at: 2016 ASCRS/ASOA Symposium & Congress. ; May 6–10, 2016. ; New Orleans, LA. .
  9. Nevanac. EPAR summary for the public. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000818/WC500027153.pdf. Accessed June 5, 2016.
  10. Nevanac 1 mg/mL eye drops, suspension [package insert]. Puurs, Belgium: S.A. Alcon-Couvreur N.V; 2015.
  11. Tzelikis PF, Vieira M, Hida WT, et al. Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular edema after phacoemulsification: prospective placebo-controlled randomized study. Br J Ophthalmol. 2015;99(5):654–658. doi:10.1136/bjophthalmol-2014-305803 [CrossRef]
  12. Kim SJ, Schoenberger SD, Thorne JE, Ehlers JP, Yeh S, Bakri SJ. Topical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American Academy of Ophthalmology. Ophthalmology. 2015;122(11):2159–2168. doi:10.1016/j.ophtha.2015.05.014 [CrossRef]
  13. Guo S, Patel S, Baumrind B, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol. 2015;60(2):123–137. doi:10.1016/j.survophthal.2014.08.005 [CrossRef]
  14. Heier JS, Topping TM, Baumann W, Dirks MS, Chern S. Combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107(11):2034–2039. doi:10.1016/S0161-6420(00)00365-1 [CrossRef]
  15. Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg. 2003;29(12):2378–2384. doi:10.1016/S0886-3350(03)00233-5 [CrossRef]
  16. Sivaprasad S, Bunce C, Crosby-Nwaobi R. Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews. 2012Feb15;(2):CD004239.
  17. Yannuzzi LA, Klein RM, Wallyn RH, Cohen N, Katiz I. Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. Am J Ophthalmol. 1977;84(4):517–519. doi:10.1016/0002-9394(77)90444-5 [CrossRef]
  18. Burnett J, Tessler H, Isenberg S, Tso MO. Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surg. 1983;14(2):150–152.
  19. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol. 1987;103(4):479–486. doi:10.1016/S0002-9394(14)74268-0 [CrossRef]
  20. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol. 1991;112(5):514–519. doi:10.1016/S0002-9394(14)76851-5 [CrossRef]
  21. Hariprasad SM, Callanan D, Gainey S, He YG, Warren K. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J Ocul Pharmacol Ther. 2007;23(6):585–590. doi:10.1089/jop.2007.0062 [CrossRef]
  22. Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol. 2009;3:147–154. doi:10.2147/OPTH.S4684 [CrossRef]
  23. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation. 2003;27(5):281–291. doi:10.1023/A:1026024409826 [CrossRef]
  24. Friedman SM, Almukhtar TH, Baker CW, et al. Topical nepafenac in eyes with noncentral diabetic macular edema. Retina. 2015;35(5):944–956. doi:10.1097/IAE.0000000000000403 [CrossRef]
  25. Sahoo S, Barua A, Myint KT, Haq A, Abas AB, Nair NS. Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema. Cochrane Database Syst Rev. 2015(2):CD010009.
  26. Allegri P, Murialdo U, Peri S, et al. Randomized, double-blind, placebo-controlled clinical trial on the efficacy of 0.5% indomethacin eye drops in uveitic macular edema. Invest Ophthalmol Vis Sci. 2014;55(3):1463–1470. doi:10.1167/iovs.13-13202 [CrossRef]
  27. Hariprasad SM, Callanan D, Gainey S, et al. Topical nepafenac 0.1% for treatment of chronic uveitic cystoid macular edema. Retin Cases Brief Rep. 2008;2(4):304–308. doi:10.1097/ICB.0b013e31809ed9db [CrossRef]
  28. Radwan AE, Arcinue CA, Yang P, Artornsombudh P, Abu Al-Fadl EM, Foster CS. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1801–1806. doi:10.1007/s00417-013-2309-4 [CrossRef]
  29. Jampel HD. Ophthalmic technology assessments. Ophthalmology. 2015;122(11):2157–2158. doi:10.1016/j.ophtha.2015.09.025 [CrossRef]
Authors

10.3928/23258160-20160808-02

Sign up to receive

Journal E-contents